Screener
Gyre Therapeutics, Inc. GYRE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Gyre Therapeutics, Inc.’s reported figures.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s EBITDA?
- Gyre Therapeutics, Inc. (GYRE) reported EBITDA of -$12.88M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s EBITDA changed year-over-year?
- Gyre Therapeutics, Inc.'s EBITDA decreased by 946.3% year-over-year, from -$1.23M to -$12.88M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s EBITDA?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s EBITDA has grown at a -52.2% compound annual growth rate (CAGR), from -$87.6M to $9.56M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Gyre Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude